Story
Spire Healthcare Gains as Takeover Deadline Extended Amid £1.3B Property Deal
Summary
Shares of the UK hospital operator rose after its second-largest shareholder, Toscafund, was granted a third extension for its takeover offer, a move supported by a recent £1.3 billion property transaction.
Spire Healthcare shares edged higher in Tuesday trading, bucking a cautious trend in the broader UK market, after the deadline for a potential takeover offer was extended for a third time and a major property deal was finalized.
Takeover Deadline Extended
The UK's Takeover Panel granted Toscafund Asset Management a new deadline of August 6, 2026, to either announce a firm intention to make an offer for Spire or walk away. This extends the previous "put up or shut up" deadline, which was set to expire today, according to a report from Investing.com.
Toscafund, which is Spire's second-largest shareholder with an 18% stake, first made a non-binding proposal in May 2026. Key details of the potential bid include:
- An offer price of 250 pence per share.
- A total valuation for the private hospital group of approximately £1 billion.
- An indication from Spire's board that it would be likely to recommend the offer to shareholders if it were formalized.
Property Sale Bolsters Valuation
AdA secondary catalyst supporting Spire's stock was the completion of a significant real estate transaction. A portfolio of 12 Spire-operated acute-care hospitals was acquired by Blue Owl Capital and Moor Park Capital Partners for approximately £1.3 billion.
This deal is seen by market participants as a validation of the underlying real estate value within Spire's asset portfolio. For investors, the transaction reinforces the investment case underpinning Toscafund's takeover proposal by confirming the tangible asset value of the company.
Market Impact
Spire's ability to gain ground occurred against a challenging macroeconomic backdrop, with the mid-cap FTSE 250 index, of which Spire is a member, trading cautiously amid geopolitical tensions. The company-specific merger and acquisition activity is currently dominating investor focus, allowing the stock to diverge from wider market weakness.